Lynn T Matthews1, Heather B Ribaudo, Angela Kaida, Kara Bennett, Nicholas Musinguzi, Mark J Siedner, Jerome Kabakyenga, Peter W Hunt, Jeffrey N Martin, Yap Boum, Jessica E Haberer, David R Bangsberg. 1. *Division of Infectious Disease, Center for Global Health, Massachusetts General Hospital, Boston, MA; †Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA; ‡Faculty of Health Sciences, Simon Fraser University, Burnaby BC, Canada; §Bennett Statistical Consulting, Ballston Lake, NY; ‖Mbarara University of Science and Technology, Mbarara, Uganda; Departments of ¶Medicine, and #Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA; **Epicentre Mbarara, Mbarara, Uganda; ††Department of General Medicine, Center for Global Health, Massachusetts General Hospital, Boston, MA.
Abstract
BACKGROUND: HIV-infected women risk sexual and perinatal HIV transmission during conception, pregnancy, childbirth, and breastfeeding. We compared HIV-1 RNA suppression and medication adherence across periconception, pregnancy, and postpartum periods, among women on antiretroviral therapy (ART) in Uganda. METHODS: We analyzed data from women in a prospective cohort study, aged 18-49 years, enrolled at ART initiation and with ≥1 pregnancy between 2005 and 2011. Participants were seen quarterly. The primary exposure of interest was pregnancy period, including periconception (3 quarters before pregnancy), pregnancy, postpartum (6 months after pregnancy outcome), or nonpregnancy related. Regression models using generalized estimating equations compared the likelihood of HIV-1 RNA ≤400 copies per milliliter, <80% average adherence based on electronic pill caps (medication event monitoring system), and likelihood of 72-hour medication gaps across each period. RESULTS: One hundred eleven women contributed 486 person-years of follow-up. Viral suppression was present at 89% of nonpregnancy, 97% of periconception, 93% of pregnancy, and 89% of postpartum visits, and was more likely during periconception (adjusted odds ratio, 2.15) compared with nonpregnant periods. Average ART adherence was 90% [interquartile range (IQR), 70%-98%], 93% (IQR, 82%-98%), 92% (IQR, 72%-98%), and 88% (IQR, 63%-97%) during nonpregnant, periconception, pregnant, and postpartum periods, respectively. Average adherence <80% was less likely during periconception (adjusted odds ratio, 0.68), and 72-hour gaps per 90 days were less frequent during periconception (adjusted relative risk, 0.72) and more frequent during postpartum (adjusted relative risk, 1.40). CONCLUSIONS: Women with pregnancy were virologically suppressed at most visits, with an increased likelihood of suppression and high adherence during periconception follow-up. Increased frequency of 72-hour gaps suggests a need for increased adherence support during postpartum periods.
BACKGROUND:HIV-infectedwomen risk sexual and perinatal HIV transmission during conception, pregnancy, childbirth, and breastfeeding. We compared HIV-1 RNA suppression and medication adherence across periconception, pregnancy, and postpartum periods, among women on antiretroviral therapy (ART) in Uganda. METHODS: We analyzed data from women in a prospective cohort study, aged 18-49 years, enrolled at ART initiation and with ≥1 pregnancy between 2005 and 2011. Participants were seen quarterly. The primary exposure of interest was pregnancy period, including periconception (3 quarters before pregnancy), pregnancy, postpartum (6 months after pregnancy outcome), or nonpregnancy related. Regression models using generalized estimating equations compared the likelihood of HIV-1 RNA ≤400 copies per milliliter, <80% average adherence based on electronic pill caps (medication event monitoring system), and likelihood of 72-hour medication gaps across each period. RESULTS: One hundred eleven women contributed 486 person-years of follow-up. Viral suppression was present at 89% of nonpregnancy, 97% of periconception, 93% of pregnancy, and 89% of postpartum visits, and was more likely during periconception (adjusted odds ratio, 2.15) compared with nonpregnant periods. Average ART adherence was 90% [interquartile range (IQR), 70%-98%], 93% (IQR, 82%-98%), 92% (IQR, 72%-98%), and 88% (IQR, 63%-97%) during nonpregnant, periconception, pregnant, and postpartum periods, respectively. Average adherence <80% was less likely during periconception (adjusted odds ratio, 0.68), and 72-hour gaps per 90 days were less frequent during periconception (adjusted relative risk, 0.72) and more frequent during postpartum (adjusted relative risk, 1.40). CONCLUSIONS:Women with pregnancy were virologically suppressed at most visits, with an increased likelihood of suppression and high adherence during periconception follow-up. Increased frequency of 72-hour gaps suggests a need for increased adherence support during postpartum periods.
Authors: Ann E Deschamps; Eric Van Wijngaerden; Kris Denhaerynck; Sabina De Geest; Anne-Mieke Vandamme Journal: J Acquir Immune Defic Syndr Date: 2006-10-01 Impact factor: 3.731
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Jean B Nachega; Michael Hislop; David W Dowdy; Richard E Chaisson; Leon Regensberg; Gary Maartens Journal: Ann Intern Med Date: 2007-04-17 Impact factor: 25.391
Authors: Beverly E Sha; Camlin Tierney; Susan E Cohn; Xin Sun; Robert W Coombs; Lisa M Frenkel; Spyros A Kalams; Francesca T Aweeka; Barbara Bastow; Arlene Bardeguez; Anne Kmack; Alice Stek Journal: HIV Clin Trials Date: 2011 Jan-Feb
Authors: Elvin H Geng; Mwebesa B Bwana; Jerome Kabakyenga; Winnie Muyindike; Nneka I Emenyonu; Nicholas Musinguzi; Peter Mugyenyi; Jeffrey N Martin; David R Bangsberg Journal: PLoS One Date: 2010-11-24 Impact factor: 3.240
Authors: Jessica H Oyugi; Jayne Byakika-Tusiime; Kathleen Ragland; Oliver Laeyendecker; Roy Mugerwa; Cissy Kityo; Peter Mugyenyi; Thomas C Quinn; David R Bangsberg Journal: AIDS Date: 2007-05-11 Impact factor: 4.177
Authors: Katherine B Rucinski; Sheree R Schwartz; Kimberly A Powers; Brian W Pence; Benjamin H Chi; Vivian Black; Helen Rees; Audrey E Pettifor Journal: AIDS Behav Date: 2020-06
Authors: Kathleen Miller; Winnie Muyindike; Lynn T Matthews; Michael Kanyesigye; Mark J Siedner Journal: AIDS Patient Care STDS Date: 2017-06-26 Impact factor: 5.078
Authors: Catherine A Koss; Paul Natureeba; Dalsone Kwarisiima; Mike Ogena; Tamara D Clark; Peter Olwoch; Deborah Cohan; Jaffer Okiring; Edwin D Charlebois; Moses R Kamya; Diane V Havlir Journal: J Acquir Immune Defic Syndr Date: 2017-03-01 Impact factor: 3.731
Authors: Lisa M Bebell; Mark J Siedner; Nicholas Musinguzi; Yap Boum; Bosco M Bwana; Winnie Muyindike; Peter W Hunt; Jeffrey N Martin; David R Bangsberg Journal: Int J STD AIDS Date: 2016-09-20 Impact factor: 1.359
Authors: Lisa M Bebell; Joseph Ngonzi; Mark J Siedner; Winnie R Muyindike; Bosco M Bwana; Laura E Riley; Yap Boum; David R Bangsberg; Ingrid V Bassett Journal: AIDS Care Date: 2018-02-16
Authors: D Joseph Davey; S West; V Umutoni; S Taleghani; H Klausner; E Farley; R Shah; S Madni; S Orewa; V Kottamasu; V Rice; Z Robbin; K M Wall Journal: AIDS Behav Date: 2018-09
Authors: Vivek Jain; Wei Chang; Dathan M Byonanebye; Asiphas Owaraganise; Ellon Twinomuhwezi; Gideon Amanyire; Douglas Black; Elliot Marseille; Moses R Kamya; Diane V Havlir; James G Kahn Journal: PLoS One Date: 2015-12-03 Impact factor: 3.240